Bylvay denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Bylvay as Not FDA-Approved

A "not FDA-approved" denial for Bylvay from Blue Cross Blue Shield is almost always a data or administrative error. Bylvay (odevixibat) holds FDA approval for its labeled indication. This type of denial typically arises from a lag in the insurer's internal drug database, a mismatch between the NDC code submitted on the claim and the plan's formulary records, or a reviewer applying a policy that has not yet been updated after the drug's approval date. It is among the most straightforwardly reversible denials.

## Why It Is Appealable

FDA approval is a matter of public record. The approval letter and the complete prescribing information are available on the FDA's website. If the prescribed use is consistent with that approved labeling, BCBS cannot sustain a "not FDA-approved" denial. Federal law protects your right to challenge:

• ACA §2719 / ERISA §503: Full internal appeal plus independent external review by an IRO.
• External review window: Generally four months from the final internal denial notice — verify the exact deadline on your Explanation of Benefits.
• Expedited review: If delay would seriously jeopardize your health, you may request expedited external review; decisions are typically required within 72 hours.

## Appeal Process and Timeline

1. Request the denial in full writing and ask BCBS to cite the specific basis for the not-FDA-approved finding. 2. Print the FDA approval documentation from FDA.gov, including the approval letter and the current full prescribing information confirming the indication. 3. Verify the NDC and drug name on the original claim submission — a billing code error can trigger this denial and may be correctable with a simple resubmission. 4. File the internal appeal attaching the FDA documentation, the prescribing information, and the prescription as written. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA approval evidence: Current FDA label for Bylvay (odevixibat), available at DailyMed or FDA.gov, confirming the approval date and approved indication.
• Prescription as written: Confirm the drug name, NDC, and indication on the prescription match the FDA label.
• Diagnosis confirmation: Chart notes confirming the underlying diagnosis falls within the labeled indication.
• Prescriber cover letter: A brief letter clarifying the on-label nature of the prescription and requesting immediate coverage reversal.

## Criteria-Mapping Structure

This appeal is unusually straightforward: map the FDA approval documentation directly to the policy requirement. If the plan's policy requires FDA approval, and the drug has it, the denial criterion is not met. Your prescriber's letter and the FDA label together constitute a complete response.